M3, Inc. · TSE:2413

M3 — Merger or Acquisition (September 2024)

13 slides from M3's merger presentation, Sep 19, 2024

  1. Slide 1: Capital and Business Alliance with ELAN Corporation

    M3, Inc. Capital and Business Alliance with ELAN Corporation September 2024 Copyright © 2024 M3, Inc. All rights reserved. 0

  2. Slide 2: Forward-looking statements disclaimer

    This document contains forward-looking statements relating to M3 and its company group, including forecasts, plans, and goals. These statements are made on the basis of projections based on information currently available to us as of the time this document was prepared. Further, these statements are

  3. Slide 3: Tender offer restrictions in the United States

    The Tender Offer will not be conducted, directly or indirectly, in or targeted at the United States, nor through the U.S. postal mail services or other interstate or international commercial methods or means (including, but not limited to, telephone, telex, facsimile, e-mail, and Internet communicat

  4. Slide 4: Overview of the Tender Offer

    Overview of the Tender Offer  Tender offer price: 1,040 yen (Total amount: approx. 31.5 to 35 billion yen)  Premium： 23.96% to 839 yen, the closing price of the target share on September 18, 2024** Key Terms and 買付金額：  26.37% ［1,600］円（株式取得総額：［1,397］億円） to 823 yen, the simple average of the closin

  5. Slide 5: Financial and Earnings Impact

    Financial and Earnings Impact  The amount required for this deal is approximately 31.5 to 35 billion yen – The full amount is to be covered by cash on hand.  For FY Mar/25, earnings are expected to increase even after considering amortization of intangible assets, and the impact on EPS will be pos

  6. Slide 6: Overview of ELAN Corporation

    Overview of ELAN Corporation Main businesses Location Matsumoto, Nagano, Japan  Medical and nursing care- related business (CS Set) Established – Providing everyday items such February, 1995 as clothing and towels to hospitalized patients and users of Capital JPY 573 million medical institutions an

  7. Slide 7: Aim of the offer: to-C Platform Fortification

    Aim of the offer： to-C Platform Fortification End-user Coverage Service Line-up Unit: Gross users Approx. Approx. (Services well fit to ELAN users) 5 million 13 million Ask PSP Doctors Approx. Home-care Clinical Hospice 8 million Nursing Trial M3 DigiKar Smart Online Telehealth Medication Consulting

  8. Slide 8: Collaborations and Synergies that are expected

    Collaborations and Synergies that are expected  By acquiring patient contacts through ELAN, M3 will expand the to-C platform for which we provide services Promoting new business  CS Set: ELAN will enhance its competitiveness and boost development and enhancing the added value by collaborations wit

  9. Slide 9: Examples: Challenges and Solutions

    １ New Business Examples: Challenges and Solutions ２ ３ ４ Creation Added Value Enhancement Before During After Discharge hospitalization hospitalization Patients  Selecting an  Burden of preparing for  Selecting a home appropriate hospital hospitalization, healthcare provider after for admission wa

  10. Slide 10: Growth in No. of Client Hospitals

    １ Cross-selling Growth in No. of Client Hospitals ２ ３ ４ to Both Business Partners Present Future M3 Group Approx. 6,000 sites ELAN 1,399 sites It is possible to significantly increase the number of client hospitals through mutual customer introductions. Accelerate the development of business partner

  11. Slide 11: IT Support for subsidiaries

    １ Better IT Support for subsidiaries ２ Productivity ３ More Competitive ４ Advantages  In-house resources provision for system-related support  System development-related costs, including outsourcing, reduced by in-house development Company A Company B Company C (IT solution provider for medical (Pr

  12. Slide 12: Our Global Physician Platform

    １ Support for Our Global Physician Platform ２ ３ Overseas ４ Expansion Ratio of physician members (As of June 2024) M3 will support ELAN's overseas expansion by utilizing its global platform and know-how in overseas M&A *The no. of physicians in Japan is based on data from the Ministry of Health, Labo

  13. Slide 13: Copyright © 2024 M3, Inc. All rights reserved.

    Copyright © 2024 M3, Inc. All rights reserved. 12

M3 — Merger or Acquisition (September 2024) on 6ix